Bimekizumab versus Secukinumab in Plaque Psoriasis
Bimekizumab versus Secukinumab in Plaque Psoriasis
About this item
Full title
Bimekizumab versus Secukinumab in Plaque Psoriasis
Author / Creator
Publisher
United States: Massachusetts Medical Society
Journal title
The New England journal of medicine, 2021-07, Vol.385 (2), p.142-152
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
Bimekizumab, which has activity against interleukin-17A and interleukin-17F, was compared in a randomized trial with secukinumab, which has activity against interleukin-17A only. Over 48 weeks, treatment with bimekizumab resulted in greater clearance of psoriasis but was associated with oral candidiasis.
Alternative Titles
Full title
Bimekizumab versus Secukinumab in Plaque Psoriasis
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2518221119
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2518221119
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa2102383
